- Home
- RXST vs PHVS Comparison
RXST vs PHVS Comparison
Compare RXST & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RXST
- PHVS
- Stock Information
- Founded
- RXST 1997
- PHVS 2015
- Country
- RXST United States
- PHVS Netherlands
- Employees
- RXST N/A
- PHVS N/A
- Industry
- RXST Biotechnology: Electromedical & Electrotherapeutic Apparatus
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- RXST Health Care
- PHVS Health Care
- Exchange
- RXST Nasdaq
- PHVS Nasdaq
- Market Cap
- RXST 1.2B
- PHVS 1.0B
- IPO Year
- RXST 2021
- PHVS 2021
- Fundamental
- Price
- RXST $32.41
- PHVS $19.32
- Analyst Decision
- RXST Strong Buy
- PHVS Strong Buy
- Analyst Count
- RXST 8
- PHVS 5
- Target Price
- RXST $58.13
- PHVS $40.60
- AVG Volume (30 Days)
- RXST 651.8K
- PHVS 46.4K
- Earning Date
- RXST 02-26-2025
- PHVS 11-13-2024
- Dividend Yield
- RXST N/A
- PHVS N/A
- EPS Growth
- RXST N/A
- PHVS N/A
- EPS
- RXST N/A
- PHVS N/A
- Revenue
- RXST $128,293,000.00
- PHVS N/A
- Revenue This Year
- RXST $60.24
- PHVS N/A
- Revenue Next Year
- RXST $35.42
- PHVS N/A
- P/E Ratio
- RXST N/A
- PHVS N/A
- Revenue Growth
- RXST 67.52
- PHVS N/A
- 52 Week Low
- RXST $26.29
- PHVS $15.21
- 52 Week High
- RXST $66.54
- PHVS $33.00
- Technical
- Relative Strength Index (RSI)
- RXST 40.40
- PHVS 54.04
- Support Level
- RXST $30.39
- PHVS $15.21
- Resistance Level
- RXST $31.80
- PHVS $19.59
- Average True Range (ATR)
- RXST 1.92
- PHVS 1.41
- MACD
- RXST 0.24
- PHVS 0.26
- Stochastic Oscillator
- RXST 56.46
- PHVS 87.63
About RXST RxSight Inc.
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The Company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.